Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity

Journal of Medicinal Chemistry

Volumn 51, Issue 15, 2008, Pages 4476-4481

  Anzini, Maurizio ^a   Rovini, Michele ^a   Cappelli, Andrea ^a   Vomero, Salvatore ^a   Manetti, Fabrizio ^a   Botta, Maurizio ^a   Sautebin, Lidia ^b   Rossi, Antonietta ^b,c   Pergola, Carlo ^b   Ghelardini, Carla ^d   Norcini, Monica ^d   Giordani, Antonio ^e   Makovec, Francesco ^e   Anzellotti, Paola ^f   Patrignani, Paola ^f   Biava, Mariangela ^g  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e Rotta Research Laboratorium   (Italy)

^f UNIVERSITY OF CHIETI   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PYRROLE DERIVATIVE; ROFECOXIB; VALDECOXIB;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; BINDING SITE; CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; EDEMA; FEMALE; HUMAN; HYPERALGESIA; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; RAT; STATISTICAL SIGNIFICANCE;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; COMPUTER SIMULATION; CYCLOOXYGENASE 2 INHIBITORS; EDEMA; ETHER, ETHYL; HUMANS; HYDROPHOBICITY; MALE; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRROLES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 49449083101     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800084s     Document Type: Article

References (29)

1. Marnett, L. J.; Rowlinson, S. W.; Goodwin, D. C.; Kalgutkar, A. S,; Lanzo, C.A. Arachidonic Acid Oxygenation by COX-1 and COX-2: Mechanisms of Catalysis and Inhibition. J. Biol. Chem. 1999, 274, 22903-22906.
2. Kulmacz, R. J.; Wang, L. H. Comparison of Hydroperoxide Initiator Requirements for the Cyclooxygenase Activities of Prostaglandin H Synthase-1 and -2. J. Biol. Chem. 1995, 270, 24019-24023.
3. Reddy, S. T.; Herschman, H. R. Ligand-Induced Prostaglandin Synthesis Requires Expression of the TIS10/PGS-2 Prostaglandin Synthase Gene in Murine Fibroblasts and Macrophages. J. Biol. Chem. 1994, 269, 15473-15480.
4. Kozak, K. R.; Prusakiewicz, J. J.; Marnett, L. J. Oxidative Metabolism of Endocannabinoids by COX-2. Curr. Pharm. Des. 2004, 10, 659-667.
5. Simmons, D. L.; Botting, R. M.; Hla, T. Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition. Pharmacol Rev. 2004, 56, 387-437.
6. Capone, M. L.; Tacconelli, S.; Di Francesco, L.; Sacchetti, A.; Sciulli, M. G.; Patrignani, P. Pharmacodynamic of Cyclooxygenase Inhibitors in Humans. Prostaglandins Other Lipid Mediators 2007, 82, 85-94.
7. Fitzgerald, G. A.; Patrono, C. The Coxibs, Selective Inhibitors of Cyclooxygenase-2. N. Engl. J. Med. 2001, 345, 433-442.
8. Wolfe, M. M.; Lichtenstein, D. R.; Singh, G. Gastrointestinal Toxicity of Nonsteroidal Anti-Inflammatory Drugs. N. Engl. J. Med. 1999, 340, 1888-1899.
9. DeWitt, D. L. Cox-2-Selective Inhibitors: The New Super Aspirins. Mol. Pharm. 1999, 55, 625-631.
10. Grosser, T.; Fries, S.; Fitzgerald, G. A. Biological Basis for the Cardiovascular Consequences of COX-2 Inhibition: Therapeutic Challenges and Opportunities. J. Clin. Invest. 2006, 116, 4-15.
11. Hernandez-Diaz, S.; Varas-Lorenzo, C.; Garcia Rodriguez, L. A. Nonsteroidal Anti-Inflammatory Drugs and the Risk of Acute Myocardial Infarction. Basic Clin. Pharmacol. Toxicol. 2006, 98, 266-274.
12. Rodriguez, L. A.; Patrignani, P. The Ever Growing Story of Cyclooxygenase Inhibition. Lancet 2006, 368, 1745-1747.
13. Fries, S.; Grosser, T.; Price, T. S.; Lawson, J. A.; Kapoor, S.; De Marco, S.; Pletcher, M. T.; Wiltshire, T.; FitzGerald, G. A. Marked Interindividual Variability in the Response to Selective Inhibitors of Cyclooxygenase-2. Gastroenterology 2006, 130, 55-64.
14. Kargman, S.; O'Neill, G. P.; Vickers, P. J.; Evans, J. F.; Mancini, J. A.; Jothy, S. Expression of Prostaglandin G/H Synthase-1 and -2 Protein in Human Colon Cancer. Cancer Res. 1995, 55, 2556-2559.
15. Biava, M.; Porretta, G. C.; Cappelli, A.; Vomero, S.; Manetti, F.; Botta, M.; Sautebin, L.; Rossi, A.; Makovec, F.; Anzini, M. 1,5-Diarylpyrrole-3-acetic Acid and Esters as Novel Classes of Potent and Highly Selective Cyclooxygenase-2 Inhibitors. J. Med. Chem. 2005, 48, 3428-3432.
16. Di Bari, L.; Pescitelli, G.; Salvadori, P.; Rovini, M.; Anzini, M.; Cappelli, A.; Vomero, S. Synthesis, Resolution, and Absolute Configuration of two Novel and Selective Cyclooxygenase-2 Inhibitors Based on 1,5-Diarylpyrrole Scaffold. Tetrahedron: Asymmetry 2006, 17, 3430-3436.
17. Biava, M.; Porretta, G. C.; Poce, G.; Supino, S.; Forli, S.; Rovini, M.; Cappelli, A.; Manetti, F.; Botta, M.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Vivoli, E.; Makovec, F.; Anzellotti, P.; Patrignani, P.; Anzini, M. Cyclooxygenase-2 Inhibitors. 1,5-Diarylpyrrole-3-acetic Esters with Enhanced Inhibitory Activity toward Cyclooxygenase-2 and Improved Cyclooxygenase-2/ Cyclooxygenase-1 Selectivity. J. Med. Chem. 2007, 50, 5403-5411.
18. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural Basis for Selective Inhibition of Cyclooxygenase-2 by Anti-inflammatory Agents. Nature 1996, 384, 644-648.
19. Swinney, D. C.; Mak, A. Y.; Barnett, J.; Ramesha, C. S. Differential Allosteric Regulation of Prostaglandin H Synthase-1 and -2 by Arachidonic acid. J. Biol. Chem. 1997, 272, 12393-12398.
20. Tacconelli, S.; Capone, M. L.; Sciulli, M. G.; Ricciotti, E.; Patrignani, P. The Biochemical Selectivity of Novel COX-2 Inhibitors in Whole Blood Assays of COX-Isozyme Activity. Curr. Med. Res. Opin. 2002, 18, 503-511.
21. Zingarelli, B.; Southan, G. J.; Gilad, E.; O'Connor, M.; Salzman, A. L.; Szabò, C. The Inibitory Effects of Mercaptoalkylguanidines on Cyclooxygenase Activity. Br. J. Pharmacol. 1997, 120, 357-366.
22. Patrignani, P.; Panara, M. R.; Greco, A.; Fusco, O.; Natoli, C.; Iacobelli, S.; Cipollone, F.; Ganci, A.; Crèminon, C.; Maclouf, J.; Patrono, C. Biochemical and Pharmacological Characterization of the Cyclooxygenase Activity of Human Blood Prostaglandin Endoperoxide Synthases. J. Pharmacol. Exp. Ther. 1994, 271, 1705-1712.
23. Patrono, C.; Ciabattoni, G.; Pinea, E.; Pugliese, F.; Castrucci, G.; De Salvo, A.; Satta, M. A.; Peskar, B. A. Low Dose Aspirin and Inhibition of Thromboxane B2 Production in Healthy Subjects. Thromb. Res. 1980, 17, 317-327.
24. Leighton, G. E.; Rodriguez, R. E.; Hill, R. G.; Hughes, J. κ-Opioid Agonists Produce Antinociception After iv and icv but not Intrathecal Administration in the Rat. Br. J. Pharmacol. 1988, 93, 553-560.
25. Koster, R.; Anderson, M.; de Beer, E. J. Acetic Acid for Analgesic Screening. Fed. Proc. 1959, 18, 412-418.
26. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated Docking Using a Lamarckian Genetic Algorithm and Empirical Binding Free Energy Function. J. Comput. Chem. 1998, 19, 1639-1662.
27. Grid, version 21; Molecular Discovery Ltd.: Marsh Road, Pinner, Middlesex, UK.
28. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. Macromodel, An Integrated Software System for Modeling Organic and Bioorganic Molecules Using Molecular Mehanics. J. Comput. Chem. 1990, 11, 440-467.
29. Soliva, R.; Almansa, C.; Kalko, S. G.; Luque, F. J.; Orozco, M. Theoretical studies on the inhibition mechanism of cyclooxygenase-2. Is there a unique recognition site. J. Med. Chem. 2003, 46, 1372-1382.